Polyunsaturated fatty acids induce ovarian cancer cell death through ROS-dependent MAP kinase activation

Biochem Biophys Res Commun. 2017 Nov 4;493(1):468-473. doi: 10.1016/j.bbrc.2017.08.168. Epub 2017 Sep 4.

Abstract

Free fatty acids not only play a role in cell membrane construction and energy production but also exert diverse cellular effects through receptor and non-receptor mechanisms. Moreover, epidemiological and clinical studies have so far suggested that polyunsaturated fatty acids (PUFAs) could have health benefits and the advantage as therapeutic use in cancer treatment. However, the underlying mechanisms of PUFA-induced cellular effects remained to be cleared. Here, we examined the effects of ω-3 and ω-6 PUFAs on cell death in ovarian cancer cell lines. ω-3 PUFA, docosahexaenoic acid (DHA) and ω-6 PUFA, γ-linolenic acid (γ-LNA) induced cell death in KF28 cells at the levels of physiological concentrations, but not HAC2 cells. Pharmacological and biochemical analyses demonstrated that cell death induced by DHA and γ-LNA was correlated with activation of JNK and p38 MAP kinases, and further an upstream MAP kinase kinase, apoptosis signal-regulating kinase 1, which is stimulated by reactive oxygen species (ROS). Furthermore, an antioxidant vitamin E attenuated PUFA-induced cell death and MAP kinase activation. These findings indicate that PUFA-induced cell death involves ROS-dependent MAP kinase activation and is a cell type-specific action. A further study of the underlying mechanisms for ROS-dependent cell death induced by PUFAs will lead to the discovery of a new target for cancer therapy or diagnosis.

Keywords: Apoptosis signal-regulating kinase 1; Docosahexaenoic acid; MAP kinase; Ovarian cancer cell death; Polyunsaturated fatty acid; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Fatty Acids, Unsaturated / administration & dosage*
  • Female
  • Humans
  • MAP Kinase Signaling System / drug effects
  • Mitogen-Activated Protein Kinase Kinases / metabolism*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism*
  • Reactive Oxygen Species / metabolism*

Substances

  • Fatty Acids, Unsaturated
  • Reactive Oxygen Species
  • Mitogen-Activated Protein Kinase Kinases